SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (1912)10/27/2003 7:08:18 PM
From: tuck  Read Replies (1) of 3044
 
Erik,

That seems a little harsh. Bayer has to prioritize the way it spends its R&D dollars, even though they have more leeway in this area than the average biotech. Perhaps some of them could be outlicensed to third parties? Perhaps the sheer scale of the project is what slowed it down; obviously there was considerable overlap in the indications that the targets . . . targeted. So a lot of decisions had to be made.

I suppose it would be better, from the strictly financial viewpoint of MLNM shareholders, if Bayer selected dozens of targets and had to pay for all of them, but that is not realistic.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News